Injectable gel releases osteoarthritis drugs for weeks

Scientists have developed an injectable hydrogel that can remain within arthritic joints for several weeks, gradually releasing medication while simultaneously enhancing joint lubrication. The gel’s viscoelastic properties allow it to conform to the joint space, creating a sustained reservoir that delivers therapeutic agents directly to damaged cartilage and synovial tissue.

The new platform could simplify the delivery of disease‑modifying drugs, such as biologics or small‑molecule inhibitors, by concentrating their action in the affected joint and reducing systemic exposure. Early preclinical studies show that the gel not only maintains drug levels over an extended period but also improves joint function by restoring synovial fluid viscosity, a key factor in reducing pain and inflammation.

If the technology translates successfully into human trials, it may offer a more targeted and convenient treatment option for patients with osteoarthritis or rheumatoid arthritis, potentially lowering the frequency of injections and minimizing off‑target side effects associated with conventional systemic therapies.